Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Predictors for the development of microalbuminuria and interaction with renal function.

Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope LM, Rump C, Mertens PR, Haller H.

J Hypertens. 2017 Dec;35(12):2501-2509. doi: 10.1097/HJH.0000000000001491.

PMID:
29035939
2.

A pragmatic lifestyle modification programme reduces the incidence of predictors of cardio-metabolic disease and dysglycaemia in a young healthy urban South Asian population: a randomised controlled trial.

Wijesuriya M, Fountoulakis N, Guess N, Banneheka S, Vasantharajah L, Gulliford M, Viberti G, Gnudi L, Karalliedde J.

BMC Med. 2017 Aug 30;15(1):146. doi: 10.1186/s12916-017-0905-6.

3.

Increased Arterial Stiffness is an Independent Predictor of Renal Function Decline in Patients With Type 2 Diabetes Mellitus Younger Than 60 Years.

Fountoulakis N, Thakrar C, Patel K, Viberti G, Gnudi L, Karalliedde J.

J Am Heart Assoc. 2017 Mar 30;6(4). pii: e004934. doi: 10.1161/JAHA.116.004934.

4.

Improvements in stage of change correlate to changes in dietary intake and clinical outcomes in a 5-year lifestyle intervention in young high-risk Sri Lankans.

Guess N, Vasantharajah L, Gulliford M, Viberti G, Gnudi L, Karalliedde J, Wijesuriya M.

Prev Med. 2016 Sep;90:193-200. doi: 10.1016/j.ypmed.2016.07.011. Epub 2016 Jul 9.

PMID:
27404575
5.

The effect of dietary changes on distinct components of the metabolic syndrome in a young Sri Lankan population at high risk of CVD.

Guess N, Wijesuriya M, Vasantharajah L, Gulliford M, Viberti G, Gnudi L, Karalliedde J.

Br J Nutr. 2016 Aug;116(4):719-27. doi: 10.1017/S0007114516002476. Epub 2016 Jun 30.

PMID:
27358019
6.

Liver fluke (Fasciola hepatica) naturally infecting introduced European brown hare (Lepus europaeus) in northern Patagonia: phenotype, prevalence and potential risk.

Cuervo PF, Cataldo SD, Fantozzi MC, Deis E, Isenrath GD, Viberti G, Artigas P, Peixoto R, Valero MA, Sierra RM, Mas-Coma S.

Acta Parasitol. 2015 Sep;60(3):536-43. doi: 10.1515/ap-2015-0076.

PMID:
26204194
7.

Diabetes. Excess mortality in well-controlled T1DM without renal disease.

Karalliedde J, Viberti G.

Nat Rev Nephrol. 2015 Mar;11(3):132-4. doi: 10.1038/nrneph.2014.249. Epub 2015 Jan 20.

PMID:
25599623
8.

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.

Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M.

BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180.

10.

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH.

J Am Soc Nephrol. 2014 May;25(5):1083-93. doi: 10.1681/ASN.2013080830. Epub 2014 Apr 10.

11.

Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.

Hoekman J, Lambers Heerspink HJ, Viberti G, Green D, Mann JF, de Zeeuw D.

Clin J Am Soc Nephrol. 2014 Mar;9(3):490-8. doi: 10.2215/CJN.07040713. Epub 2014 Jan 9.

12.

Commentary: the birth of microalbuminuria: a milestone in the history of medicine.

Viberti G, Karalliedde J.

Int J Epidemiol. 2014 Feb;43(1):18-20. doi: 10.1093/ije/dyt256. Epub 2013 Dec 27. No abstract available.

PMID:
24374830
13.

Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.

Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1899-905. doi: 10.2215/CJN.02700313. Epub 2013 Aug 8.

14.

Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.

Viswanathan V, Mohan V, Subramani P, Parthasarathy N, Subramaniyam G, Manoharan D, Sundaramoorthy C, Gnudi L, Karalliedde J, Viberti G.

Clin J Am Soc Nephrol. 2013 Feb;8(2):225-32. doi: 10.2215/CJN.06330612. Epub 2012 Nov 26.

15.

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Plüddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR.

Diabetologia. 2012 Oct;55(10):2593-2603. doi: 10.1007/s00125-012-2653-7. Epub 2012 Aug 10. Review. Erratum in: Diabetologia. 2012 Dec;55(12):3399-400.

PMID:
22875195
16.

Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.

Menne J, Izzo JL Jr, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H; ROADMAP investigators.

J Hypertens. 2012 Apr;30(4):811-8; discussion 818. doi: 10.1097/HJH.0b013e328351856d. Erratum in: J Hypertens. 2012 Aug;30(8):1679.

PMID:
22418908
17.

High prevalence of cardio-metabolic risk factors in a young urban Sri-Lankan population.

Wijesuriya M, Gulliford M, Charlton J, Vasantharaja L, Viberti G, Gnudi L, Karalliedde J.

PLoS One. 2012;7(2):e31309. doi: 10.1371/journal.pone.0031309. Epub 2012 Feb 13.

18.

DIABRISK-SL prevention of cardio-metabolic disease with life style modification in young urban Sri Lankan's--study protocol for a randomized controlled trial.

Wijesuriya M, Gulliford M, Vasantharajah L, Viberti G, Gnudi L, Karalliedde J.

Trials. 2011 Sep 26;12:209. doi: 10.1186/1745-6215-12-209.

19.

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE; ADOPT Study Group.

Clin J Am Soc Nephrol. 2011 May;6(5):1032-40. doi: 10.2215/CJN.09291010. Epub 2011 Mar 31.

20.

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; ADOPT Study Group.

Diabetes. 2011 May;60(5):1552-60. doi: 10.2337/db10-1392. Epub 2011 Mar 17.

21.

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.

N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.

22.

Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).

Januszewicz A, Ritz E, Viberti G, Mimran A, Rabelink AJ, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Haller H.

J Hum Hypertens. 2011 Nov;25(11):679-85. doi: 10.1038/jhh.2010.111. Epub 2010 Dec 9.

PMID:
21150933
23.

Proteinuria in diabetes: bystander or pathway to cardiorenal disease?

Karalliedde J, Viberti G.

J Am Soc Nephrol. 2010 Dec;21(12):2020-7. doi: 10.1681/ASN.2010030250. Epub 2010 Nov 4. Review.

24.

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.

Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, Wieczorek Kirk D.

Int J Cardiol. 2011 Sep 1;151(2):136-42. doi: 10.1016/j.ijcard.2010.08.037. Epub 2010 Sep 15.

PMID:
20837369
25.

Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.

Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, Bilous R, Hiroshi K, Gruden G, Viberti G, Gnudi L.

Am J Nephrol. 2010;32(5):393-402. doi: 10.1159/000320129. Epub 2010 Sep 3.

PMID:
20814199
26.

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.

Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee.

Diabetologia. 2010 Sep;53(9):1838-45. doi: 10.1007/s00125-010-1804-y. Epub 2010 Jun 8.

27.

Avosentan for overt diabetic nephropathy.

Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group.

J Am Soc Nephrol. 2010 Mar;21(3):527-35. doi: 10.1681/ASN.2009060593. Epub 2010 Feb 18.

28.

Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria.

Dessapt C, Karalliedde J, Hernandez-Fuentes M, Prieto Martin P, Maltese G, Dattani N, Atkar R, Viberti G, Gnudi L.

Diabetes Care. 2010 Apr;33(4):875-7. doi: 10.2337/dc09-1468. Epub 2010 Jan 12.

29.

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H.

Diabetologia. 2010 Jan;53(1):49-57. doi: 10.1007/s00125-009-1577-3. Epub 2009 Oct 30.

30.

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.

Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE; ADOPT Study Group.

J Clin Endocrinol Metab. 2010 Jan;95(1):134-42. doi: 10.1210/jc.2009-0572. Epub 2009 Oct 29.

PMID:
19875477
31.

Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria.

Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G.

J Hypertens. 2010 Jan;28(1):186-93. doi: 10.1097/HJH.0b013e328332bd61.

PMID:
19809363
32.

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group.

Diabetes Care. 2010 Jan;33(1):177-83. doi: 10.2337/dc09-1661. Epub 2009 Oct 6.

33.

Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation.

Dessapt C, Baradez MO, Hayward A, Dei Cas A, Thomas SM, Viberti G, Gnudi L.

Nephrol Dial Transplant. 2009 Sep;24(9):2645-55. doi: 10.1093/ndt/gfp204. Epub 2009 May 6.

PMID:
19420102
34.

Evaluation of rosiglitazone administration on cardiovascular function in severe obesity.

Brunani A, Liuzzi A, Titon A, Graci S, Castagna G, Viberti GC, Gondoni LA.

Clin Cardiol. 2008 Dec;31(12):602-6. doi: 10.1002/clc.20339.

35.

Genetic association analyses of non-synonymous single nucleotide polymorphisms in diabetic nephropathy.

Savage DA, Patterson CC, Deloukas P, Whittaker P, McKnight AJ, Morrison J, Boulton AJ, Demaine AG, Marshall SM, Millward BA, Thomas SM, Viberti GC, Walker JD, Sadlier D, Maxwell AP, Bain SC.

Diabetologia. 2008 Nov;51(11):1998-2002. doi: 10.1007/s00125-008-1142-5. Epub 2008 Sep 5.

36.

Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice.

Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, Marshall S, Viberti G, Gnudi L.

Diabetes. 2008 Oct;57(10):2824-33. doi: 10.2337/db08-0647. Epub 2008 Jul 22.

37.

Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.

Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G.

Hypertension. 2008 Jun;51(6):1617-23. doi: 10.1161/HYPERTENSIONAHA.108.111674. Epub 2008 Apr 21.

PMID:
18426991
38.

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group.

Diabetes Care. 2008 May;31(5):845-51. doi: 10.2337/dc07-2270. Epub 2008 Jan 25.

PMID:
18223031
39.

Screening for chronic kidney disease in patients with diabetes: are we missing the point?

Thomas MC, Viberti G, Groop PH.

Nat Clin Pract Nephrol. 2008 Jan;4(1):2-3. Epub 2007 Nov 27. No abstract available.

PMID:
18043592
40.

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R.

J Hypertens. 2007 Sep;25(9):1921-6.

PMID:
17762658
41.

Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism.

Gnudi L, Thomas SM, Viberti G.

J Am Soc Nephrol. 2007 Aug;18(8):2226-32. Epub 2007 Jul 18. Review.

42.

Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia.

Davis B, Dei Cas A, Long DA, White KE, Hayward A, Ku CH, Woolf AS, Bilous R, Viberti G, Gnudi L.

J Am Soc Nephrol. 2007 Aug;18(8):2320-9. Epub 2007 Jul 11.

43.

HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes.

Groop PH, Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, Taskinen MR, Viberti G.

Diabetes Care. 2007 Oct;30(10):2706-7. Epub 2007 Jul 9. No abstract available.

PMID:
17620444
44.

Hyperhomocysteinemia in winter elite athletes: a longitudinal study.

Borrione P, Pigozzi F, Massazza G, Schonhuber H, Viberti G, Paccotti P, Angeli A.

J Endocrinol Invest. 2007 May;30(5):367-75.

PMID:
17598967
45.

Misleading meta-analysis: a need to look beyond the headlines.

Chaturvedi N, Bilous R, Hardy R, Remuzzi G, Ruggenenti P, Viberti GC.

Diabet Med. 2007 Jun;24(6):587-91. Epub 2007 May 8. No abstract available.

PMID:
17490423
46.
47.

Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.

Brunani A, Caumo A, Graci S, Castagna G, Viberti G, Liuzzi A.

Diabetes Obes Metab. 2008 Jun;10(6):460-7. Epub 2007 Mar 29.

PMID:
17394563
48.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.

N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.

49.

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH; ADOPT Study Group.

Diabet Med. 2006 Dec;23(12):1289-94.

PMID:
17116177
50.

The link between mechanical stretch and glucose metabolism--a conceptual advance in understanding diabetic (and non diabetic?) renal disease.

Gnudi L, Viberti G.

Nephrol Dial Transplant. 2007 Feb;22(2):318-21. Epub 2006 Nov 18. No abstract available.

PMID:
17114798

Supplemental Content

Loading ...
Support Center